Literature DB >> 26282165

STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.

Jasmine Lau1, Shirin Ilkhanizadeh2, Susan Wang3, Yekaterina A Miroshnikova4, Nicolas A Salvatierra2, Robyn A Wong2, Christin Schmidt2, Valerie M Weaver5, William A Weiss6, Anders I Persson7.   

Abstract

High grade gliomas (HGG) are classified into four subgroups based on transcriptional signatures and phenotypic characteristics. In particular, the proneural-to-mesenchymal transition (PMT) is associated with increased malignancy, poor prognosis, and disease recurrence, but the underlying causes of PMT are still unclear. In this study, we investigated whether radiotherapy promotes PMT using a genetically engineered mouse model of proneural HGG. We found that cranial ionizing radiation induced robust and durable PMT in tumors. Additionally, we isolated primary proneural HGG cells from mouse and human tumors and demonstrate that radiation induced a sustained cell-intrinsic mesenchymal transition associated with increased invasiveness and resistance to the alkylating agent temozolomide. Expectedly, irradiation-induced PMT was also associated with activation of the STAT3 transcription factor, and the combination of STAT3 blockade using JAK2 inhibitors with radiation abrogated the mesenchymal transition and extended survival of mice. Taken together, our data suggest that clinical JAK2 inhibitors should be tested in conjunction with radiation in patients with proneural HGG as a new strategy for blocking the emergence of therapy-resistant mesenchymal tumors at relapse. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26282165      PMCID: PMC4609277          DOI: 10.1158/0008-5472.CAN-14-3331

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.

Authors:  Lee A D Cooper; David A Gutman; Candace Chisolm; Christina Appin; Jun Kong; Yuan Rong; Tahsin Kurc; Erwin G Van Meir; Joel H Saltz; Carlos S Moreno; Daniel J Brat
Journal:  Am J Pathol       Date:  2012-03-20       Impact factor: 4.307

2.  The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.

Authors:  Lee A D Cooper; David A Gutman; Qi Long; Brent A Johnson; Sharath R Cholleti; Tahsin Kurc; Joel H Saltz; Daniel J Brat; Carlos S Moreno
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

3.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.

Authors:  Krishna P L Bhat; Katrina L Salazar; Veerakumar Balasubramaniyan; Khalida Wani; Lindsey Heathcock; Faith Hollingsworth; Johanna D James; Joy Gumin; Kristin L Diefes; Se Hoon Kim; Alice Turski; Yasaman Azodi; Yuhui Yang; Tiffany Doucette; Howard Colman; Erik P Sulman; Frederick F Lang; Ganesh Rao; Sjef Copray; Brian D Vaillant; Kenneth D Aldape
Journal:  Genes Dev       Date:  2011-12-15       Impact factor: 11.361

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

5.  Non-stem cell origin for oligodendroglioma.

Authors:  Anders I Persson; Claudia Petritsch; Fredrik J Swartling; Melissa Itsara; Fraser J Sim; Romane Auvergne; David D Goldenberg; Scott R Vandenberg; Kim N Nguyen; Stanislava Yakovenko; Jennifer Ayers-Ringler; Akiko Nishiyama; William B Stallcup; Mitchel S Berger; Gabriele Bergers; Tracy R McKnight; Steven A Goldman; William A Weiss
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

Review 6.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

7.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

Authors:  Kan V Lu; Jeffrey P Chang; Christine A Parachoniak; Melissa M Pandika; Manish K Aghi; David Meyronet; Nadezda Isachenko; Shaun D Fouse; Joanna J Phillips; David A Cheresh; Morag Park; Gabriele Bergers
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

8.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Authors:  Albert Lai; Samir Kharbanda; Whitney B Pope; Anh Tran; Orestes E Solis; Franklin Peale; William F Forrest; Kanan Pujara; Jose A Carrillo; Ajay Pandita; Benjamin M Ellingson; Chauncey W Bowers; Robert H Soriano; Nils O Schmidt; Sankar Mohan; William H Yong; Somasekar Seshagiri; Zora Modrusan; Zhaoshi Jiang; Kenneth D Aldape; Paul S Mischel; Linda M Liau; Cameron J Escovedo; Weidong Chen; Phioanh Leia Nghiemphu; C David James; Michael D Prados; Manfred Westphal; Katrin Lamszus; Timothy Cloughesy; Heidi S Phillips
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

9.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

10.  The transcriptional network for mesenchymal transformation of brain tumours.

Authors:  Maria Stella Carro; Wei Keat Lim; Mariano Javier Alvarez; Robert J Bollo; Xudong Zhao; Evan Y Snyder; Erik P Sulman; Sandrine L Anne; Fiona Doetsch; Howard Colman; Anna Lasorella; Ken Aldape; Andrea Califano; Antonio Iavarone
Journal:  Nature       Date:  2009-12-23       Impact factor: 49.962

View more
  37 in total

1.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

2.  STAT3 is a key molecule in the oncogenic behavior of diffuse intrinsic pontine glioma.

Authors:  Jinju Park; Woochan Lee; Sangil Yun; Saet Pyoul Kim; Kyung Hyun Kim; Jong-Il Kim; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

3.  MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells.

Authors:  Arun K Rooj; Franz Ricklefs; Marco Mineo; Ichiro Nakano; E Antonio Chiocca; Agnieszka Bronisz; Jakub Godlewski
Journal:  Cell Rep       Date:  2017-06-06       Impact factor: 9.423

4.  PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.

Authors:  Zijie Gao; Jianye Xu; Yang Fan; Yanhua Qi; Shaobo Wang; Shulin Zhao; Xing Guo; Hao Xue; Lin Deng; Rongrong Zhao; Chong Sun; Ping Zhang; Gang Li
Journal:  J Exp Clin Cancer Res       Date:  2022-07-15

5.  P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells.

Authors:  Sree Deepthi Muthukrishnan; Riki Kawaguchi; Pooja Nair; Rachna Prasad; Yue Qin; Maverick Johnson; Qing Wang; Nathan VanderVeer-Harris; Amy Pham; Alvaro G Alvarado; Michael C Condro; Fuying Gao; Raymond Gau; Maria G Castro; Pedro R Lowenstein; Arjun Deb; Jason D Hinman; Frank Pajonk; Terry C Burns; Steven A Goldman; Daniel H Geschwind; Harley I Kornblum
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

Review 6.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway.

Authors:  Li Hong; Liu Ya-Wei; Wang Hai; Zhou Qiang; Li Jun-Jie; Annie Huang; Qi Song-Tao; Lu Yun-Tao
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

Review 8.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

9.  Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway.

Authors:  Jinquan Cai; Jinwei Zhang; Pengfei Wu; Weitong Yang; Qile Ye; Qun Chen; Chuanlu Jiang
Journal:  J Neurooncol       Date:  2018-07-24       Impact factor: 4.130

10.  Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy.

Authors:  Martina Ott; Cynthia Kassab; Anantha Marisetty; Yuuri Hashimoto; Jun Wei; Daniel Zamler; Jia-Shiun Leu; Karl-Heinz Tomaszowski; Aria Sabbagh; Dexing Fang; Pravesh Gupta; Waldemar Priebe; Rafal J Zielinski; Jared K Burks; James P Long; Ling-Yuan Kong; Gregory N Fuller; John DeGroot; Erik P Sulman; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-30       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.